Biology subjects

Mestdagh, P.

Publications and source records attributed to Mestdagh, P..

4 recordsLinked to original sources

bioRxiv2018

SMARTer single cell total RNA sequencing

Single cell RNA sequencing methods have been increasingly used to understand cellular heterogeneity. Nevertheless, most of these methods suffer from one or more limitations, such as focusing only on polyadenylated RNA, sequencing of only the 3 end of the transcript, an exuberant fraction of reads mapping to ribosomal RNA, and the unstranded nature of the sequencing data. Here, we developed a novel single cell strand-specific total RNA library preparation method addressing all the aforementioned shortcomings. Our method was validated on a microfluidics system using three different cancer cell lines undergoing a chemical or genetic perturbation. We demonstrate that our total RNA-seq method detects an equal or higher number of genes compared to classic polyA[+] RNA-seq, including novel and non-polyadenylated genes. The obtained RNA expression patterns also recapitulate the expected biological signal. Inherent to total RNA-seq, our method is also able to detect circular RNAs. Taken together, SMARTer single cell total RNA sequencing is very well suited for any single cell sequencing experiment in which transcript level information is needed beyond polyadenylated genes.

genomics↗

bioRxiv2018

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

In this study, the circulating miRNome from diagnostic neuroblastoma serum was assessed for identification of non-invasive biomarkers with potential in monitoring metastatic disease. After determining the circulating neuroblastoma miRNome, 743 miRNAs were screened in two independent cohorts of 131 and 54 patients. Evaluation of serum miRNA variance in a model testing for tumor stage, MYCN status, age at diagnosis and overall survival, revealed tumor stage as the most significant factor impacting miRNA abundance in neuroblastoma serum. Differential expression analysis between patients with metastatic and localized disease revealed 9 miRNAs strongly associated with metastatic stage 4 disease in both patient cohorts. Increasing levels of these miRNAs were also observed in serum from xenografted mice bearing human neuroblastoma tumors. Moreover, murine serum miRNA levels were strongly associated with tumor volume, suggesting this miRNA signature may be applied to monitor disease burden.

cancer biology↗

bioRxiv2017

Differential gene expression analysis tools exhibit substandard performance for long non-coding RNA-sequencing data

BackgroundProtein-coding RNAs (mRNA) have been the primary target of most transcriptome studies in the past, but in recent years, attention has expanded to include long non-coding RNAs (lncRNA). lncRNAs are typically expressed at low levels, and are inherently highly variable. This is a fundamental challenge for differential expression (DE) analysis. In this study, the performance of 14 popular tools for testing DE in RNA-seq data along with their normalization methods is comprehensively evaluated, with a particular focus on lncRNAs and low abundant mRNAs.\n\nResultsThirteen performance metrics were used to evaluate DE tools and normalization methods using simulations and analyses of six diverse RNA-seq datasets. Non-parametric procedures are used to simulate gene expression data in such a way that realistic levels of expression and variability are preserved in the simulated data. Throughout the assessment, we kept track of the results for mRNA and lncRNA separately. All statistical models exhibited inferior performance for lncRNAs compared to mRNAs across all simulated scenarios and analysis of benchmark RNA-seq datasets. No single tool uniformly outperformed the others.\n\nConclusionOverall, the linear modeling with empirical Bayes moderation (limma) and the nonparametric approach (SAMSeq) showed best performance: good control of the false discovery rate (FDR) and reasonable sensitivity. However, for achieving a sensitivity of at least 50%, more than 80 samples are required when studying expression levels in a realistic clinical settings such as in cancer research. About half of the methods showed severe excess of false discoveries, making these methods unreliable for differential expression analysis and jeopardizing reproducible science. The detailed results of our study can be consulted through a user-friendly web application, http://statapps.ugent.be/tools/AppDGE/

genomics↗

bioRxiv2017

Targeted genomic screen reveals focal long non-coding RNA copy number alterations in cancer

The landscape of somatic copy-number alterations (SCNAs) affecting long non-coding RNAs (lncRNAs) in human cancer remains largely unexplored. While the majority of lncRNAs remains to be functionally characterized, several have been implicated in cancer development and metastasis. Considering the plethora of lncRNAs genes that is currently reported, it is conceivable that several lncRNAs might function as oncogenes or tumor suppressor genes.\n\nWe devised a strategy to detect focal lncRNA SCNAs using a custom DNA microarray platform probing 20 418 lncRNA genes. By screening a panel of 80 cancer cell lines, we detected numerous focal aberrations targeting one or multiple lncRNAs without affecting neighboring protein-coding genes. These focal aberrations are highly suggestive for a tumor suppressive or oncogenic role of the targeted lncRNA gene. Although functional validation remains an essential step in the further characterization of the involved candidate cancer lncRNAs, our results provide a direct way of prioritizing candidate lncRNAs involved in cancer pathogenesis.

genetics↗